Last reviewed · How we verify
Dextromethorphan HBr
Dextromethorphan HBr is a sigma-1 receptor agonist and NMDA receptor antagonist that reduces cough by suppressing the cough reflex center in the medulla.
Dextromethorphan HBr is a sigma-1 receptor agonist and NMDA receptor antagonist that reduces cough by suppressing the cough reflex center in the medulla. Used for Cough suppression (OTC/marketed indication), Oral mucositis (potential pipeline indication under Galera development).
At a glance
| Generic name | Dextromethorphan HBr |
|---|---|
| Sponsor | Galera Therapeutics, Inc. |
| Drug class | NMDA receptor antagonist; sigma-1 receptor agonist |
| Target | NMDA receptor; sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Supportive Care; Respiratory |
| Phase | FDA-approved |
Mechanism of action
Dextromethorphan acts primarily as a non-competitive NMDA receptor antagonist, which suppresses cough signals in the central nervous system. It also exhibits sigma-1 receptor agonist activity, which may contribute to neuroprotective and anti-inflammatory effects. When formulated by Galera Therapeutics (likely as GalEra or in combination formulations), it may be investigated for additional therapeutic benefits beyond cough suppression, potentially including oral mucositis prevention or other supportive care indications.
Approved indications
- Cough suppression (OTC/marketed indication)
- Oral mucositis (potential pipeline indication under Galera development)
Common side effects
- Dizziness
- Drowsiness
- Nausea
- Constipation
Key clinical trials
- Dextromethorphan for Treatment of Postoperative Pain (NA)
- Psilocybin-facilitated Treatment for Chronic Pain (EARLY_PHASE1)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia (PHASE2, PHASE3)
- Investigation of Psychedelic Effects in Psychoactive Substances (PHASE1)
- A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin (PHASE4)
- An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study (PHASE3)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextromethorphan HBr CI brief — competitive landscape report
- Dextromethorphan HBr updates RSS · CI watch RSS
- Galera Therapeutics, Inc. portfolio CI